Phase II Study of Cladribine Plus Low Dose Cytarabine (LDAC) Induction Followed By Consolidation With Cladribine Plus LDAC Alternating With Decitabine in Patients With Untreated Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2017
At a glance
- Drugs Cladribine (Primary) ; Cytarabine (Primary) ; Decitabine (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 14 Feb 2017 Planned End Date changed from 1 Feb 2016 to 1 Feb 2019.
- 14 Feb 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
- 07 Mar 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018 as per ClinicalTrials.gov record.